A drug, and the test that says who it is for.
Both programs are preclinical. Nothing here has been tested in humans, and the stage chart below shows where the work actually is, not where we would like it to be.
in published cell studies
first results end of 2026
Bacterial DnaK inhibitors
Selective small molecules that block bacterial DnaK, given alongside existing chemotherapy in cancers where these bacteria are present.
The reasoning is direct. Bacterial DnaK suppresses p53, and cisplatin and 5-FU both depend on p53. In published work, blocking DnaK with a binding peptide restored the activity of both drugs in human colorectal and gastric cancer cell lines, and improved their anti-cancer effect by 25% in primary tumor cells from a DnaK-expressing mouse. See the paper →
We are deliberately building something that goes with chemotherapy instead of replacing it. The claim is narrower and the regulatory path cleaner, and it fits how oncologists already work.
Tens of candidate molecules are being evaluated by using several assays in vitro and in vivo which model potential safety, efficacy and off-target effects. The screen will narrow with GATC Health's predictive AI platform and its Derisq™ reports, with first results expected end of 2026 and final results in 2027. Read the announcement →
Companion diagnostic
We are laying the framework to identify and measure bacterial DnaK, paving the way for precision medicine.
It is the nearer-term piece of work and the one that makes the therapeutic targetable. A drug aimed at a bacterial protein only helps people who have the protein.
It also stands on its own clinically. Knowing that a patient's tumor carries a bacterial protein suppressing p53 is information an oncologist has no way of getting today.
The next step is finishing development and preparing for regulatory review.
Everything above is investigational. No DnaK Therapeutics candidate has been tested in humans, and none is approved by the FDA or any other regulator for any use. Preclinical research runs at USF CONNECT in Tampa, Florida. Findings referred to as in-vivo are from animal models.
Not a replacement for chemotherapy. A way to make it work better.